Pds Biotechnology Corporation · NASDAQ:PDSB
Pds Biotechnology — Investor Presentation (April 2026)
21 slides from Pds Biotechnology's investor presentation, Apr 24, 2026
Slide 1: Precision Designed Science for Cancer Patients
Precision Designed Science for Cancer Patients NASDAQ: PDSB April 2026
Slide 2: Forward-Looking Statements
Forward-Looking Statements This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corpo
Slide 3: Targeting HPV16+ Cancers: Registrational Trial, Compelling Clinical Data
months 12-18 months for current standard of care1 Keytrud (pembrolizumab) benchmark in First-line (1L) treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (1L R/M HNSCC) 77.4% disease control rate with PDS0101 in 1L R/M HNSCC Phase 3 VERSATILE-003 pivotal trial FDA alignment on
Slide 4: HPV16+ Tumors Represent the Largest and Fastest Growing Type of HNSCC
HPV16 HPV18 HPV 31/33/45/52/58 HPV 35/39/51/56/59/68 HPV-negative HPV16+ Tumors Represent the Largest and Fastest Growing Type of HNSCC HPV16+ HNSCC Rapidly Increasing in the US and EU Poor uptake of HPV vaccine2,3 Changing sexual behavior4 Unique pathophysiology of HPV165 Annual Number of Oropharyn
Slide 5: HPV16+ Patients Have No Targeted Therapies and Worse Clinical Outcomes
PUBLISHED EVIDENCE Two head-to-head studies demonstrate that HPV16-positive patients have statistically worse survival compared to other patient groups: Early-stage HNSCC: HPV16+ patients had worse survival than other HPV+ (P16+) patients6 Advanced oral cancer: HPV16+ patients had worse survival tha
Slide 6: The Versamune Platform Provides Mechanism for Targeted Immune Attack
HOW IT WORKS 1 2 3 ATTACK Killer T cells hunt & destroy matching tumors Immunologically active R-enantiomer of1,2-dioleoyl-trimethyl-ammonium (R-DOTAP) R-DOTAP forms spherical bilayers in aqueous environment The Versamune® Platform Provides Mechanism for Targeted Immune Attack Proprietary immunother
Slide 7: PDS0101: Training the Immune System to Find and Destroy HPV16+ Tumors
PDS0101: Training the Immune System to Find and Destroy HPV16+ Tumors8 CD4+helper T cell CD8+killer T cell HPV16 E6 & E7 Versamune®Activated CD8+Killer T Cell ImmuneCheckpointInhibitor Versamune® +HPVmix (PDS0101) Targeted CD8+ T CellsTracks to Tumor Dendritic Cell MHC class II MHC class I LYMPH NOD
Slide 8: Pipeline
Therapy / Treatment Indication P2 P3 Partner Versamune® PDS0101 + pembrolizumab vs. pembrolizumab (VERSATILE-003) HPV16-positive recurrent/metastatic head and neck cancer PDS0101 + ChemoRT* (IMMUNOCERV) Locally advanced cervical cancer PDS0101 +/- pembrolizumab Locally advanced head and neck cancer
Slide 9: Lead Clinical Program Evaluating PDS0101 in Combination with Checkpoint Inhibitors
Endpoints Single-arm study 31 sites in US and EU 2 Cohorts: ICI Naïve ICI Resistant HPV16-positive R/M HNSCC tumors ≥18 years of age Combined positive score (CPS) ≥1 PDS0101 5 doses: 1 mL Subcutaneous injection Q3W at Cycles 1, 2, 3, 4 & 12) + Pembrolizumab 200mg IV Q3W up to 35 Cycles (2 years) Pri
Slide 10: PDS0101 + Pembrolizumab: mOS of 39.3 Months
PDS0101 + Pembrolizumab: mOS of 39.3 Months9 mOS = Median Overall Survival. No head-to-head studies have been performed. 12-18 Months mOS is Benchmark with Pembrolizumab and Pembrolizumab + Chemotherapy1 Durable Survival: 11 Patients Surpassed 30 Months
Slide 11: PDS0101: Near or Complete Tumor Shrinkage in Difficult-to-Treat Patients
PDS0101: Near or Complete Tumor Shrinkage in Difficult-to-Treat Patients9 *Investigator assessment. 63% with CPS 1-199 Confirmed disease control rate of 77.4% ORR of 35.8% 21% of patients had tumor regression of 90-100%
Slide 12: PDS0101: Well-tolerated with a Low Incidence of Adverse Events
PDS0101: Well-tolerated with a Low Incidence of Adverse Events9 *Occurred 1 year after completing PDS0101 therapy while patient was still on pembrolizumab. Treatment related adverse events (TRAEs) by Grade in ICI naïve and resistant patients n (%) Any Combination TRAE 76 (87.4) Grade 1 40 (46.0) Gra
Slide 13: VERSATILE-003: Pivotal Phase in Progress
VERSATILE-003: Pivotal Phase 3 in Progress PDS0101 + pembrolizumab in 1L HPV16-positive R/M HNSCC Key Eligibility Criteria HPV16-positive HNSCC CPS ≥1 ≥18 years of age ECOG 0-1 Primary Endpoints Overall Survival (OS) Progression free survival (PFS) Secondary Endpoints Objective Response Rate (ORR) D
Slide 14: Well-Positioned in 1L HPV16+ R/M HNSCC
Well-Positioned in 1L HPV16+ R/M HNSCC No head-to-head studies have been performed. Combinations with pembrolizumab PDS0101: Only Subcutaneous Combination Therapy in Late-stage Development for 1L HPV16+ HNSCC Genmab10 Bicara11 BioNTech12 PDS Biotech Median OS Not disclosed 21.3 months 22.6 months 39
Slide 15: PDS01ADC: Novel Investigational Tumor Targeting IL-12 Immunocytokine
Tumor-targeted IL-12 immunocytokine THE SOLUTION PDS01ADC attaches IL-12 to an antibody (NHS76) that seeks out dying tumor cells, delivering treatment directly where it's needed while minimizing systemic inflammation13,14 HOW IT WORKS Finds the TumorThe NHS76 antibody targets DNA that is exposed whe
Slide 16: Upcoming Catalysts
Enrollment completion PFS data readout (Submission of interim data to FDA) PDS01ADC + HAIP Stage 1 Cholangiocarcinoma PDS01ADC + Enzalutamide vs Enzalutamide Biochemically Recurrent Prostate cancer PDS01ADC + Docetaxel Castration Resistant Prostate cancer Final Data ReadoutPDS01ADC + HAIP Colorectal
Slide 17: Global IP Portfolio Covers Key Commercial Markets
COVERAGE Composition and method claims protecting both platform technology and product candidates 13 Patent Families PDS0101 EXCLUSIVITY 2041/2042 Global IP Portfolio Covers Key Commercial Markets 8 North America Asia Pacific Europe Middle East USA Canada Mexico EU/UK Israel China Japan Australia KE
Slide 18: PDS Platform is a Significant Value Creation Opportunity
HPV16+ HNSCC PDS Platform is a Significant Value Creation Opportunity Locally advanced cervical cancer Castration resistant prostate cancer HPV16+ R/M cancers Biochemically recurrent prostate cancer Metastatic colorectal & liver-associated cancers >$1.0B TOTAL ADDRESSABLE MARKET – US ONLY HPV16+ HNS
Slide 19: The PDS Opportunity
The only investigational therapy in Phase 3 with 30+ months median survival in 1L HPV16+ R/M HNSCC $1.2 - 1.8B The PDS Opportunity World-Class Research PartnersNCI, Mayo Clinic, MD Anderson and leading cancer centers with studies externally funded, independently validated Global IP Protection13 pate
Slide 20: Thank You
Thank You NASDAQ: PDSB April 2026
Slide 21: References
References Harrington, KJ, Burtness B, Greil R, et al. Keytruda With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol. 2022;41:790-802. https://doi.org/10.1200/JCO.21.02508. Damgacioglu H, Sonaw
PDS Biotechnology — Investor Presentation (April 2026) on 6ix